Display options
Cite
Yano N, Endoh M, Nomoto Y, et al. Phenotypic characterization of cytokine expression in patients with IgA nephropathy. J Clin Immunol. 1997;17(5):396-403doi: 10.1023/a:1027368308453.
Yano, N., Endoh, M., Nomoto, Y., Sakai, H., Fadden, K., & Rifai, A. (1997). Phenotypic characterization of cytokine expression in patients with IgA nephropathy. Journal of clinical immunology, 17(5), 396-403. https://doi.org/10.1023/a:1027368308453
Yano, N, et al. "Phenotypic characterization of cytokine expression in patients with IgA nephropathy." Journal of clinical immunology vol. 17,5 (1997): 396-403. doi: https://doi.org/10.1023/a:1027368308453
Yano N, Endoh M, Nomoto Y, Sakai H, Fadden K, Rifai A. Phenotypic characterization of cytokine expression in patients with IgA nephropathy. J Clin Immunol. 1997 Sep;17(5):396-403. doi: 10.1023/a:1027368308453. PMID: 9327339.
Copy Download .nbib Format: NLM
Share it on

J Clin Immunol. 1997 Sep;17(5):396-403. doi: 10.1023/a:1027368308453.

Phenotypic characterization of cytokine expression in patients with IgA nephropathy.

Journal of clinical immunology

N Yano, M Endoh, Y Nomoto, H Sakai, K Fadden, A Rifai

Affiliations

  1. Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan.

PMID: 9327339 DOI: 10.1023/a:1027368308453

Abstract

To identify the cytokines that play a relevant role in the pathogenesis of IgA nephropathy, we analyzed and compared the gene expression of proinflammatory cytokines, immuno-regulatory cytokines, and growth factors in peripheral blood mononuclear cells (PBMC). Expression of IL-1 alpha, IL-1 beta, IL-2, IL-4, IL-6, IL-10, IL-12, IFN-gamma, TGF-beta, TNF-alpha, and PDGF was examined in 28 patients with IgA nephropathy (IgAN), 20 patients with non-IgA mesangial proliferative glomerulonephritis (mesPGN), and 19 healthy controls. Compared with healthy controls, a significant number of IgAN and mesPGN patients showed increased expression of IL-1 beta, IL-4, IL-10, IL-12, and IFN-gamma. The cytokine profile of renal tissue of 10 IgAN and 5 mesPGN biopsies was simultaneously analyzed and compared with that of PBMC. The proinflammatory IL-1 alpha and growth factor PDGF-B were expressed more in renal tissues than in PBMC. Furthermore, the renal profile of IL-alpha, IFN-gamma, and TNF-alpha expression was associated with the expression of IFN-gamma in PBMC. The serum level of IFN-gamma of IgAN correlated significantly (P = 0.0003) with that of IL-12, suggesting a potential role for cross-stimulation. More importantly, expression of IFN-gamma in PBMC and the elevated serum level correlated with the decline in glomerular filtration rate (P = 0.0012) and severity of renal histopathologic grade. To elucidate the role of leukocytes in renal cytokine expression, surface markers of T cells (CD3), monocytes (CD14), natural killer cells (CD16), and B cells (CD19) were also examined in renal tissues. The prominent renal expression of CD3, CD14, and CD16 implicates the leukocytes as the major source of proinflammatory cytokines in IgAN. Collectively, these findings indicate that IFN-gamma plays a prominent role in an interactive network of cytokines that contribute to the pathogenesis and progression of IgA nephropathy.

References

  1. Kidney Int. 1990 Aug;38(2):249-57 - PubMed
  2. Lab Invest. 1994 Apr;70(4):435-6 - PubMed
  3. Lab Invest. 1994 Apr;70(4):449-59 - PubMed
  4. J Immunol. 1987 Oct 15;139(8):2669-74 - PubMed
  5. Kidney Int. 1994 Sep;46(3):862-8 - PubMed
  6. Nihon Jinzo Gakkai Shi. 1984 Sep;26(9):1179-85 - PubMed
  7. J Immunol. 1995 Feb 15;154(4):1606-13 - PubMed
  8. Nephron. 1993;64(1):159-60 - PubMed
  9. J Immunol. 1995 May 1;154(9):4341-50 - PubMed
  10. Proc Natl Acad Sci U S A. 1985 May;82(9):2935-9 - PubMed
  11. Clin Exp Immunol. 1992 May;88(2):295-300 - PubMed
  12. J Clin Immunol. 1996 Jan;16(1):71-9 - PubMed
  13. Kidney Int. 1992 Mar;41(3):557-9 - PubMed
  14. Nephron. 1991;57(3):257-61 - PubMed
  15. J Exp Med. 1991 Oct 1;174(4):915-24 - PubMed
  16. Nature. 1990 Jul 26;346(6282):371-4 - PubMed
  17. Lab Invest. 1991 Jul;65(1):61-6 - PubMed
  18. Kidney Int. 1992 Mar;41(3):604-6 - PubMed
  19. J Immunol. 1989 Dec 15;143(12):3949-55 - PubMed
  20. J Immunol. 1988 Aug 1;141(3):713-20 - PubMed
  21. Nephron. 1992;62(2):169-75 - PubMed
  22. J Immunol. 1995 May 15;154(10):5492-9 - PubMed
  23. Am J Kidney Dis. 1994 Feb;23(2):242-6 - PubMed
  24. Clin Immunol Immunopathol. 1984 Mar;30(3):362-73 - PubMed
  25. Kidney Int. 1992 Feb;41(2):297-309 - PubMed
  26. Nephron. 1996;72(1):44-51 - PubMed
  27. J Immunol. 1986 May 15;136(10):3700-5 - PubMed
  28. Kidney Int. 1994 Aug;46(2):341-9 - PubMed
  29. Kidney Int Suppl. 1992 May;36:S15-20 - PubMed
  30. Clin Exp Immunol. 1991 Aug;85(2):240-5 - PubMed
  31. Kidney Int. 1995 Feb;47(2):377-87 - PubMed
  32. Anal Biochem. 1987 Apr;162(1):156-9 - PubMed
  33. Kidney Int. 1992 Mar;41(3):566-70 - PubMed
  34. J Immunol. 1988 Sep 15;141(6):2050-6 - PubMed
  35. Kidney Int. 1993 Dec;44(6):1298-308 - PubMed
  36. Hum Immunol. 1996 Aug;49(1):64-70 - PubMed
  37. Kidney Int. 1992 Aug;42(2):341-53 - PubMed

Substances

MeSH terms

Publication Types

Grant support